Therapeutics News and Research

RSS

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorization under exceptional circumstances for NEZGLYAL® (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd)-negative brain lesions.

26 Sep 2026

UCLA researchers present new radiation advances at ASTRO 2026

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share new research and clinical trial findings at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on new treatment approaches for prostate, bile duct and head and neck cancers, personalized radiation therapy based on genetic risk, and advances in targeted radiation and radioligand therapy designed to improve cancer control while limiting treatment side effects.

25 Sep 2026

Engineers use the human body to transmit wireless device signals

Using the human body to transmit signals, Georgia Tech engineers have created a wireless networking system that allows tiny implantable sensors and actuators to communicate with each other as well as wearable devices.

25 Sep 2026

Better storage buffers could pave way for safer mRNA therapies

Researchers at The University of Texas at Austin have teamed up with pharmaceutical leader Eli Lilly and Company to uncover new information about mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other important treatments, and how to make it more effective.

25 Sep 2026

New project aims to make cellular therapies more accessible through room temperature storage

The Advanced Research Projects Agency for Health, or ARPA-H, has executed an award of up to $36.5 million in support of a University of California, Davis-led project aiming to make cellular therapies cheaper and more accessible through room temperature storage.

25 Sep 2026

In vivo CAR-T therapy transforms customized treatments into universal medicines

A collaborative team led by Professor Huji Xu from Naval Medical University, China, together with Professors Xuanming Yang and Yujia Cai at Shanghai Jiao Tong University, China, published a comprehensive review in Volume 2, article number 33 of the journal Immunity & Inflammation on August 31, 2026.

25 Sep 2026

Leica Biosystems brings Tempus pathology products to Aperio AI Store, accelerating AI-powered capabilities for oncology research

The Aperio AI Store integrates Tempus' AI applications, transforming complex pathology images into research insights and accelerating cancer diagnostics.

From Leica Biosystems 25 Sep 2026

EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapies

Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes.

24 Sep 2026

Protein modification network plays vital role in cancer development

A review published in Genes & Diseases highlights the complex interplay between protein arginine methylation and ubiquitination, two forms of protein modification that can profoundly influence cancer development, progression and treatment response.

24 Sep 2026

Review highlights how altered metabolism drives kidney cancer growth

Clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer, is increasingly understood as a malignancy shaped by profound changes in cellular metabolism.

24 Sep 2026

Mount Sinai researchers discover how Alzheimer's gene damages blood vessels

Mount Sinai researchers have identified how APOE4, the strongest genetic risk factor for Alzheimer's disease, damages the brain's blood vessels and promotes the buildup of abnormal proteins linked to neurodegenerative disease.

24 Sep 2026

Multiple immunosuppressive therapies increase infection risks for cancer patients

Retrospective analysis of more than 20,000 patient records identifies opportunities for risk-mitigating approaches in certain patient populations.

24 Sep 2026

Early treatment may improve outcomes in Shwachman-Diamond syndrome

More than 90% of children born with the rare bone marrow condition called Shwachman-Diamond Syndrome (SDS) survive beyond age 20. But fewer than 30% live beyond age 50.

23 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026

PsychAD studies map molecular mechanisms across major brain disorders

Research led by Mount Sinai scientists within the PsychAD Consortium, a large-scale, multidisciplinary initiative launched in 2019 with support from the National Institute on Aging (NIA), is featured in a landmark collection of nine papers published across the Nature family of journals that maps the molecular mechanisms underlying Alzheimer's disease, Parkinson's disease, schizophrenia, and other brain disorders.

23 Sep 2026

Experimental drug reverses multiple sclerosis damage in mouse model

A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis.

23 Sep 2026

C-Path awards $1.7 million to advance five drug development projects

Critical Path Institute (C-Path) today announced that its Translational Therapeutics Accelerator has awarded $1,699,500 through five Bridging Research and Innovation in Drug Development Grants (BRIDGe).

22 Sep 2026

Novel computing platform models brain cell changes in autism

This technology introduces an advanced neural network model and specialized hardware architecture designed to analyze and identify synaptic dysfunctions related to Autism Spectrum Disorders and similar complex neurological conditions.

22 Sep 2026

Binghamton University scientists win seed funding for medical technologies

Two Binghamton University faculty members will receive seed funding through the State University of New York (SUNY) Technology Accelerator Fund (TAF), which provides grants to faculty inventors and scientists.

22 Sep 2026

Marine carbohydrates offer valuable new resources for drug development

The ocean contains diverse carbohydrates that could serve as valuable resources for drug development. Algae, marine animals and microorganisms produce polysaccharides and related molecules with structures that are uncommon on land, including distinctive sulfate patterns, sugar linkages and branched architectures.

22 Sep 2026